We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+47.89%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$214M
AUM Growth
+$38.2M
Cap. Flow
-$12.5M
Cap. Flow %
-5.84%
Top 10 Hldgs %
59.94%
Holding
87
New
14
Increased
17
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$3.66M
2
VIR icon
Vir Biotechnology
VIR
+$2.09M
3
ABVX
Abivax
ABVX
+$1.92M
4
HALO icon
Halozyme
HALO
+$1.58M
5
BIOA
BioAge Labs
BIOA
+$1.25M

Top Sells

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$4.04M
2
CMPS
Compass Pathways
CMPS
+$3.5M
3
GPCR icon
Structure Therapeutics
GPCR
+$3.36M
4
OCUL icon
Ocular Therapeutix
OCUL
+$2.71M
5
NVCR icon
NovoCure
NVCR
+$2.21M

Sector Composition

Rank Sector Weight
1 Healthcare 63.39%
2 Technology 32.27%
3 Energy 3.51%
4 Materials 0.53%
5 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAMP icon
51
CAMP4 Therapeutics
CAMP
$277M
$524K 0.25%
+120,000
New +$517K
SVRA icon
52
Savara
SVRA
$1.1B
$493K 0.23%
+80,000
New +$429K
CADL icon
53
Candel Therapeutics
CADL
$978M
$492K 0.23%
47,756
-12,244
-20% -$92.5K
ALT icon
54
Altimmune
ALT
$665M
$464K 0.22%
+152,681
New +$456K
CMPS
55
Compass Pathways
CMPS
$1.84B
$425K 0.2%
30,000
-345,000
-92% -$3.5M
KPTI icon
56
Karyopharm Therapeutics
KPTI
$40.6M
$420K 0.2%
42,952
-41,000
-49% -$356K
CGEM icon
57
Cullinan Oncology
CGEM
$1.42B
$364K 0.17%
20,000
– –
TRIN icon
58
Trinity Capital Inc
TRIN
$1.73B
$358K 0.17%
20,000
– –
CAPR icon
59
Capricor Therapeutics
CAPR
$547M
$346K 0.16%
+14,352
New +$435K
CSTL icon
60
Castle Biosciences
CSTL
$1.01B
$310K 0.14%
12,984
+84
+0.7% +$1.87K
IVVD icon
61
Invivyd
IVVD
$243M
$299K 0.14%
+342,275
New +$429K
GRCE
62
Grace Therapeutics
GRCE
$44.2M
$272K 0.13%
120,000
+70,000
+140% +$194K
KBDC
63
Kayne Anderson BDC
KBDC
$888M
$271K 0.13%
20,000
– –
VYGR icon
64
Voyager Therapeutics
VYGR
$216M
$263K 0.12%
75,147
+229
+0.3% +$868
LUNG icon
65
Pulmonx
LUNG
$94.9M
$261K 0.12%
200,543
-49,678
-20% -$68.4K
OCUL icon
66
Ocular Therapeutix
OCUL
$2.34B
$203K 0.09%
20,655
-299,345
-94% -$2.71M
KYNB
67
Kyntra Bio
KYNB
$34.6M
$170K 0.08%
22,566
– –
ELUT icon
68
Elutia
ELUT
$36.4M
$162K 0.08%
165,094
– –
QNRX
69
Quoin Pharmaceuticals
QNRX
$14.6M
$96.8K 0.05%
20,000
– –
LPCN icon
70
Lipocine
LPCN
$20.2M
$42.8K 0.02%
16,712
-95,074
-85% -$229K
DCGO icon
71
DocGo
DCGO
$39.8M
$20.2K 0.01%
39,062
-511
-1% -$305
GOSS icon
72
Gossamer Bio
GOSS
$85.7M
$2.99K ﹤0.01%
18,176
– –
APGE icon
73
Apogee Therapeutics
APGE
– –
-9,000
Closed -$758K
APLS
74
DELISTED
Apellis Pharmaceuticals
APLS
– –
-14,000
Closed -$563K
ENGN icon
75
enGene Therapeutics
ENGN
$122M
– –
-250,000
Closed -$1.7M
1 2
3
4

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Birchview Capital held 87 positions worth $214M, up 22% from $176M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Birchview Capital withdrew a net $12.5M in Q2 2026, closing 15 positions and reducing 22 holdings. Its most notable exit was NovoCure, an estimated $2.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Technology and Energy.

Against the trend, Birchview Capital opened a new position in Vir Biotechnology worth $2.24M.

  • Birchview Capital's largest Q2 2026 buy was Vir Biotechnology: 220,000 shares worth $2.24M.
  • Birchview Capital added most to Nektar Therapeutics in Q2 2026, an estimated $3.66M increase.
  • Birchview Capital's biggest Q2 2026 reduction was KLA, cutting an estimated $4.04M.
  • Birchview Capital fully exited NovoCure in Q2 2026, selling an estimated $2.21M.
  • Birchview Capital's ten largest holdings make up 60% of its $214M portfolio in Q2 2026.
  • Birchview Capital opened 14 new positions and closed 15 in Q2 2026.
  • Birchview Capital's portfolio value rose 22% quarter-over-quarter to $214M.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.